Cardura Pfizer (doxazosin mesylate)

Cardura is a well-known prescription medication used primarily to treat high blood pressure (hypertension) and the symptoms of benign prostatic hyperplasia (BPH). Its active ingredient, doxazosin mesylate, belongs to a class of drugs called alpha-blockers, which work by relaxing the muscles in the blood vessels and prostate.

The brand has a complex ownership history tied to the evolution of the pharmaceutical giant Pfizer. Originally developed and launched by Pfizer, the brand was part of its established medicines portfolio for decades. In November 2020, Pfizer spun off its Upjohn division (which housed its off-patent and legacy brands like Cardura) and merged it with Mylan to form a new independent company called Viatris. Consequently, while the 'Pfizer' name is still frequently associated with Cardura due to its historical origin, the ultimate ownership and commercial rights for the brand in many global markets, including the United States, now reside with Viatris.

Manufacturing of Cardura takes place in multiple locations globally. Viatris operates a vast network of roughly 40 manufacturing sites across six continents, with major production hubs in countries such as India, Ireland, Germany, and Italy. Pfizer also maintains its own extensive manufacturing footprint, often producing various pharmaceutical components or finished goods across the USA and Europe. Because it is a global brand with various generic and branded versions, the specific country of origin for a single pack can vary depending on the local distributor and regional supply chain.